Managing Organ Rejection Through Innovative Solutions

"Long before anyone else, Paul Terasaki was interested in the use of specific antilymphocyte antibodies to treat rejection…" March 2016
 

Thomas E. Starzl, MD, PhD

Professor of Surgery

University of Pittsburgh

"Paul Terasaki’s 1964 article in Nature
on the Lymphocytotoxicty Assay was the beginning of personalized medicine something that is now quite vogue to talk about was actually invented by Paul Terasaki 55 years ago…" July 2019

 

Allan Kirk, MD, PHD

Chair, Department of Surgery

Duke University

Moving the legacy of a transplant pioneer forward!

Questions: info@tictx.org

Terasaki Innovation Center, Inc. is a registered 501(c)(3) nonprofit organization
© 2020 Terasaki Innovation Center. All Rights Reserved.

  • Twitter
  • Instagram